IgA Nephropathy Care: A Shift Toward Proactive, Targeted Treatment

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/54/7c/b4/547cb433-faa2-e528-a62c-44b129cb223d/mza_2915872245149821434.jpg/600x600bb.jpg

Clinician's Roundtable

ReachMD

3197 episodes

3 days ago

Tune in to interviews with the top thought leaders in medicine exploring the clinical and professional issues that are foremost in the minds of the medical community. Join us at the Clinician's Roundtable for discussions on a vast range of topics that every medical professional should know about.

Science

Medicine

RSS

All content for Clinician's Roundtable is the property of ReachMD and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

Medicine

IgA Nephropathy Care: A Shift Toward Proactive, Targeted Treatment

Clinician's Roundtable

2 months ago

IgA Nephropathy Care: A Shift Toward Proactive, Targeted Treatment

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jonathan Barratt, MD, PhD

Delayed diagnosis and limited treatment options have historically been barriers to optimal management of IgA nephropathy (IgAN), but that paradigm may be shifting. A paper published in Kidney International in April 2025 points out that significant nephron loss often occurs before diagnosis, making early, targeted treatment essential. The paper makes the case for lowering proteinuria thresholds, minimizing steroid use, and employing safer, more effective therapies in combination. Joining Dr. Charles Turck to discuss this developing approach to IgAN care is Dr. Jonathan Barratt, the Mayor Professor of Renal Medicine at the University of Leicester in the UK and a coauthor of the study.

Reference:

Floege J, Bernier-Jean A, Barratt J, Rovin B. Treatment of patients with IgA nephropathy: a call for a new paradigm. Kidney International. 2025;S0085-2538(25)00076-6.